Schering wins injunction against Clarinex generic
Executive Summary
Ranbaxy agrees not to manufacture, market or sell generic versions of Schering's Clarinex (desloratadine) following an Aug. 28 injunction from the U.S. District Court for New Jersey. Claiming patent infringement, Schering brought the civil action against Ranbaxy in September 2006. Zydus Pharmaceuticals dropped out of the desloratadine ANDA running; similar desloratadine challenges are pending...